Patent ID: 9556164
Date: 2017-01-31
CPC Classifications: A61P,C07B,C07D

Claim:
1. A molecular crystalline substance in crystalline form, comprising a compound of formula 1 also known as Dasatinib, and a second compound selected from the group consisting of a) saccharin which crystalline substance has a PXRD pattern with at least one characteristic peak, expressed in 2θ±0.2° 2θ using CuKα radiation, selected from the following peaks located at 9.7, 13.4, 15.1, 20.4, 20.7, 21.6, 22.6, 23.5, 24.4 and 25.2° or a PXRD pattern with at least one characteristic peak, expressed in 2θ±0.2° 2θ using CuKα radiation, selected from the following peaks located 4.3, 8.0, 14.9. 20.8, 23.7 and 25.5°, b) glutaric acid which crystalline substance has a PXRD pattern with at least one characteristic peak, expressed in 2θ±0.2° 2θ using CuKα radiation, selected from the following peaks located at 5.6, 5.8, 11.1, 15.8, 16.7, 23.3, 23.5 and 25.2°, and c) nicotinic acid which crystalline substance has a PXRD pattern with at least one characteristic peak, expressed in 2θ±0.2° 2θ using CuKα radiation, selected from the following peaks located at 5.9, 11.0, 14.7, 19.9, 24.3, 25.8 and 27.3°.